Serum Golgi Protein 73 is a Prognostic Biomarker of Liver Transplantation Patients

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2020 Jan 23

PMID 31966719

Citations 3

Authors

Yufei Wang

Zhuomei Zhang

Deyong Zou

Qinfang Hao

Xueping Ma

Cui Wang

Jing Zhang

Xiaoli Zhang

Beihan Wang

Xiaoli Wang

Xiaoli Yang

Affiliations

Soon will be listed here.

Abstract

Background: The death after liver transplantation (LT) was most commonly caused by HCC recurrence. Golgi protein 73 (GP73), a type II Golgi membrane protein, has been proved to be a better serum marker for HCC.

Objective: This study aims to clarify the relationship between serum GP73 levels and tumor recurrence as well as survival of HCC patients after LT.

Methods: Between November 2003 and July 2008, serum samples from 60 liver transplantation patients and 72 healthy individuals were collected. ELISA and microparticle enzyme immunoassay were used to measure serum GP73 and AFP levels. Patient survival was analyzed using log-rank test along with Kaplan-Meier method. Receiver operating characteristic (ROC) curve was utilized to analyze the diagnostic value of serum GP73 levels. Cox regression was utilized to analyze prognostic factors with multiple variables.

Results: Serum GP73 concentrations in HCC patients were much higher than that in healthy controls (P<0.001). Patients with lower serum GP73 levels at LT-6Month had better overall survival and recurrence-free survival than those with higher serum GP73 levels. ROC analyzing results showed that higher serum GP73 levels at 6 month post-LT could significantly predict mortality (P=0.020) as well as HCC recurrence (P=0.001) after liver transplantation. Multivariate analysis revealed that serum GP73 levels at LT-6Month was an independent predictor of good prognosis (P=0.002).

Conclusion: Serum GP73 levels could be used to predict tumor recurrence and survival in HCC sufferers after LT.

Citing Articles

Development of a nomogram for predicting liver transplantation prognosis in hepatocellular carcinoma.

He L, Ji W, Jin H, Lu W, Zhang Y, Wang H World J Gastroenterol. 2024; 30(21):2763-2776.

PMID: 38899335 PMC: 11185292. DOI: 10.3748/wjg.v30.i21.2763.

Golgi protein 73, hepatocellular carcinoma and other types of cancers.

Wang Y, Wan Y Liver Res. 2020; 4(4):161-167.

PMID: 33343966 PMC: 7743997. DOI: 10.1016/j.livres.2020.09.003.

Golgi Protein 73 versus Alpha-Fetoprotein as a New Biomarker in Early Diagnosis of Hepatocellular Carcinoma.

Ali O, El Amin H, Sharkawy Y, Mohamed Ali A, Mohammed Kholef E, Elsewify W Int J Gen Med. 2020; 13:193-200.

PMID: 32547160 PMC: 7244238. DOI: 10.2147/IJGM.S253622.

References

Gupta S, Bent S, Kohlwes J . Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003; 139(1):46-50. DOI: 10.7326/0003-4819-139-1-200307010-00012. View

Gu Y, Chen W, Zhao Y, Chen L, Peng T . Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases. Ann Clin Biochem. 2008; 46(Pt 1):38-43. DOI: 10.1258/acb.2008.008088. View

Zhou Y, Jiang J, You J, Zhou L . Effect of Golgi phosphoprotein 2 (GOLPH2/GP73) on autophagy in human hepatocellular carcinoma HepG2 cells. Tumour Biol. 2014; 36(5):3399-406. DOI: 10.1007/s13277-014-2974-x. View

Brundtland G . From the World Health Organization. Reducing risks to health, promoting healthy life. JAMA. 2002; 288(16):1974. DOI: 10.1001/jama.288.16.1974. View

Roayaie S, Schwartz J, Sung M, Emre S, Miller C, Gondolesi G . Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 2004; 10(4):534-40. DOI: 10.1002/lt.20128. View

Clavien P, Lesurtel M, Bossuyt P, Gores G, Langer B, Perrier A . Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2011; 13(1):e11-22. PMC: 3417764. DOI: 10.1016/S1470-2045(11)70175-9. View

Rosenfeldt M, Ryan K . The multiple roles of autophagy in cancer. Carcinogenesis. 2011; 32(7):955-63. PMC: 3128556. DOI: 10.1093/carcin/bgr031. View

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F . Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334(11):693-9. DOI: 10.1056/NEJM199603143341104. View

Jonas S, Bechstein W, Steinmuller T, Herrmann M, Radke C, Berg T . Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001; 33(5):1080-6. DOI: 10.1053/jhep.2001.23561. View

10.

Vora S, Zheng H, Stadler Z, Fuchs C, Zhu A . Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist. 2009; 14(7):717-25. DOI: 10.1634/theoncologist.2009-0038. View

11.

Marrero J, Romano P, Nikolaeva O, Steel L, Mehta A, Fimmel C . GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005; 43(6):1007-12. DOI: 10.1016/j.jhep.2005.05.028. View

12.

Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C . Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant. 2010; 10(1):129-37. DOI: 10.1111/j.1600-6143.2009.02750.x. View

13.

Kladney R, Bulla G, Guo L, Mason A, Tollefson A, SIMON D . GP73, a novel Golgi-localized protein upregulated by viral infection. Gene. 2000; 249(1-2):53-65. PMC: 7127640. DOI: 10.1016/s0378-1119(00)00136-0. View

14.

Ding Z, Shi Y, Zhou J, Qiu S, Xu Y, Dai Z . Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma. Cancer Res. 2008; 68(22):9167-75. DOI: 10.1158/0008-5472.CAN-08-1573. View

15.

Ni H, Williams J, Yang H, Shi Y, Fan J, Ding W . Targeting autophagy for the treatment of liver diseases. Pharmacol Res. 2012; 66(6):463-74. PMC: 3502728. DOI: 10.1016/j.phrs.2012.07.003. View

16.

Chen H, Han Z, Fan J, Xia J, Wu J, Qiu G . miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver. Med Oncol. 2011; 29(3):1859-65. DOI: 10.1007/s12032-011-0031-9. View

17.

Gao G, Dong F, Xu X, Hu A, Hu Y . Diagnostic value of serum Golgi protein 73 for HBV-related primary hepatic carcinoma. Int J Clin Exp Pathol. 2015; 8(9):11379-85. PMC: 4637679. View

18.

Ba M, Long H, Tang Y, Cui S . GP73 expression and its significance in the diagnosis of hepatocellular carcinoma: a review. Int J Clin Exp Pathol. 2012; 5(9):874-81. PMC: 3484483. View

19.

Block T, Comunale M, Lowman M, Steel L, Romano P, Fimmel C . Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A. 2005; 102(3):779-84. PMC: 545516. DOI: 10.1073/pnas.0408928102. View

20.

Llovet J, Bruix J . Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003; 37(2):429-42. DOI: 10.1053/jhep.2003.50047. View